Autoantibodies against apolipoprotein A‐1 and phosphorylcholine for diagnosis of non‐ST‐segment elevation myocardial infarction

Keller, Pierre-Frédéric; Pagano, Sabrina; Roux‐Lombard, Pascale; Sigaud, Philippe; Rutschmann, Olivier Thierry; Mach, François; Hochstrasser, Denis; Vuilleumier, Nicolas

doi:10.1111/j.1365-2796.2011.02479.x

Cited by 36 publications

(87 citation statements)

References 35 publications

(88 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…148 A few years later, Vuilleumier et al found that 11-21% of ACS patients tested positive for anti-apoA-I autoantibodies compared with 20% of patients with severe internal carotid stenosis, 38% of non-STEMI patients, 29% of patients undergoing elective carotid endarterectomy, and 1-2% of healthy controls. [149][150][151][152] In fact, there was an association between high anti-apoA-I IgG titers and increased circulating levels of oxidized LDL, TNF-α, IL-6, IL-8, and matrix metalloproteinase 9 (MMP-9). 150,153,154 Accordingly, patients positive for serum anti-apoA-I IgG had decreased plaque stability, as evidenced by increased intraplaque MMP-9 levels as well as higher densities of macrophages and neutrophils within plaques.…”

Section: Anti-apoa-i Autoantibodiesmentioning

confidence: 99%

Dysfunctional high-density lipoproteins in coronary heart disease: implications for diagnostics and therapy

Annema

Eckardstein

2016

Translational Research

View full text Add to dashboard Cite

Low plasma levels of high-density lipoprotein (HDL) cholesterol are associated with increased risks of coronary heart disease. HDL mediates cholesterol efflux from macrophages for reverse transport to the liver and elicits many anti-inflammatory and anti-oxidative activities which are potentially antiatherogenic. Nevertheless, HDL has not been successfully targeted by drugs for prevention or treatment of cardiovascular diseases. One potential reason is the targeting of HDL cholesterol which does not capture the structural and functional complexity of HDL particles. Hundreds of lipid species and dozens of proteins as well as several microRNAs have been identified in HDL. This physiological heterogeneity is further increased in pathologic conditions due to additional quantitative and qualitative molecular changes of HDL components which have been associated with both loss of physiological function and gain of pathologic dysfunction. This structural and functional complexity of HDL has prevented clear assignments of molecules to the functions of normal HDL and dysfunctions of pathologic HDL. Systematic analyses of structure-function relationships of HDL-associated molecules and their modifications are needed to test the different components and functions of HDL for their relative contribution in the pathogenesis of atherosclerosis. The derived biomarkers and targets may eventually help to exploit HDL for treatment and diagnostics of cardiovascular diseases.

show abstract

Section: Anti-apoa-i Autoantibodiesmentioning

confidence: 99%

Dysfunctional high-density lipoproteins in coronary heart disease: implications for diagnostics and therapy

Annema

Eckardstein

2016

Translational Research

View full text Add to dashboard Cite

show abstract

“…Noteworthy, prospective cohort studies showed a prognostic value of ApoA1 antibodies as a predictor of unfavorable cardiovascular events in patients with MI, 102,114 severe carotid stenosis (in patients, who underwent carotid endarterectomy), 115,116 and RA. 117,118 However, all these data were obtained in a single-center (ie, based on the Geneva University Hospital) cohort studies.…”

Section: Anti-apoa1 Self-antibodies As Prognostic and Diagnostic Markmentioning

confidence: 99%

ApoA1 and ApoA1-specific self-antibodies in cardiovascular disease

Chistiakov

Orekhov

Bobryshev

2016

Laboratory Investigation

View full text Add to dashboard Cite

“…169 Autoantibodies to apoA-I are found in the plasma of the normal population at a prevalence of 1-2% but at a prevalence of 10-30% in the plasma of patients with systemic lupus erythematosus (SLE), primary antiphospholipid syndrome (APLS), or rheumatoid arthritis, as well as in the plasma of patients with acute coronary syndrome (ACS) or carotid stenosis. [195][196][197][198][199][200][201][202][203] In patients with ACS or rheumatoid arthritis high titers of anti-apoA-I-autoantibodies increase the risk of cardiovascular events or death. 199, 204 In patients with SLE or APLS the presence of anti-apoA-I-autoantibodies interferes with the antioxidant properties of HDLs by decreasing PON1 activity.…”

Section: Post-translational Modifications Of Proteinsmentioning

confidence: 99%

High-Density Lipoproteins

Annema

Eckardstein

2013

Circ J

144

View full text Add to dashboard Cite

Low plasma levels of high-density lipoprotein (HDL) cholesterol are associated with increased risks of coronary artery disease (CAD). HDL particles exert many effects in vitro and in vivo that may protect arteries from chemical or biological harm or facilitate repair of injuries. Nevertheless, HDL has not yet been successfully exploited for therapy. One potential reason for this shortfall is the structural and functional complexity of HDL particles, which carry more than 80 different proteins and more than 200 lipid species as well as several microRNAs and other potentially bioactive molecules. This physiological heterogeneity is further increased in several inflammatory conditions that increase cardiovascular risk, including CAD itself but also diabetes mellitus, chronic kidney disease, and rheumatic diseases. The quantitative and qualitative modifications of the proteome and lipidome, as well as the resulting loss of functions or gain of dysfunctions, are not recovered by the biomarker HDL-cholesterol. As yet the relative importance of the many physiological and pathological activities of normal and dysfunctional HDL, respectively, for the pathogenesis of atherosclerosis is unknown. The answer to this question, as well as detailed knowledge of structure-function-relationships of HDL-associated molecules, is a prerequisite to exploit HDL for the development of anti-atherogenic drugs as well as of diagnostic biomarkers for the identification, personalized treatment stratification, and monitoring of patients at increased cardiovascular risk. 2433Multifunctional but Vulnerable HDL munication of results. 15 As yet, clinical and epidemiological studies have come to discrepant and inconsistent conclusions on the prognostic performance of HDL subclasses differentiated by size. 14,20-24 Sometimes the associations of cardiovascular risk with the various HDL subclass concentrations were not stronger than with HDL-C, 20,21 and even if so, the associations with size were discrepant: significant associations with risk of cardiovascular events or stroke were found for small HDL in some studies, 22,23 but for medium-sized HDL 21,23 or large HDL 14,20,21,24 in others.Previous proteomic, lipidomic, and transcriptomic studies revealed a much greater structural complexity of HDLs: 80 different proteins, 25,26 more than 200 lipid species, 27,28 and several microRNAs 29,30 have been identified in HDL isolated from plasma by either ultracentrifugation, gel filtration, or immunoaffinity chromatography (Figure 1). Among the proteins, apoA-II is present in HDLs at the highest concentration after that of apoA-I and has been investigated for its cardiovascular risk association by several studies. In contrast to initial findings, large prospective studies did not find any significant differences in the risk association between apoA-II-containing and apoA-II-free HDL. [15][16][17] Despite their much lower concentrations relative to the 2 major proteins apoA-I and apoA-II and relative to the major lipids, many quantitatively minor componen...

show abstract

Autoantibodies against apolipoprotein A‐1 and phosphorylcholine for diagnosis of non‐ST‐segment elevation myocardial infarction

Cited by 36 publications

References 35 publications

Dysfunctional high-density lipoproteins in coronary heart disease: implications for diagnostics and therapy

Dysfunctional high-density lipoproteins in coronary heart disease: implications for diagnostics and therapy

ApoA1 and ApoA1-specific self-antibodies in cardiovascular disease

High-Density Lipoproteins

Contact Info

Product

Resources

About